

1        **Early Psychosis Informatics into Care [EPICare]: A co-designed protocol for**  
2        **implementing and evaluating a national integrated digital registry and clinical**  
3        **decision support system within early intervention in psychosis services**

4  
5        Siân Lowri Griffiths,<sup>1</sup> Graham K. Murray,<sup>2,3</sup> Yanakan Logeswaran,<sup>4</sup> John Ainsworth,<sup>5</sup> Sophie M.  
6        Allan,<sup>3,4</sup> Niyah Campbell,<sup>1</sup> Richard Drake,<sup>5</sup> Mohammad Zia Katshu,<sup>6</sup> Matthew Machin,<sup>5</sup> Megan A.  
7        Pope,<sup>1</sup> Sarah A. Sullivan,<sup>7,8</sup> Justin Waring,<sup>9</sup> Tumelo Bogatsu,<sup>1</sup> Julie Kane,<sup>10</sup> Tyler Weetman,<sup>10</sup> Sonia  
8        Johnson,<sup>4,11</sup> James B. Kirkbride,<sup>4\*</sup> Rachel Upthegrove<sup>1,10\*</sup>

9

10        *\*Joint senior authorship*

11

12        <sup>1</sup> Institute for Mental Health, University of Birmingham, Birmingham, UK

13        <sup>2</sup> University of Cambridge, Cambridge, UK

14        <sup>3</sup> CAMEO, Cambridgeshire and Peterborough NHS Foundation Trust

15        <sup>4</sup> University College London, London, UK

16        <sup>5</sup> The University of Manchester, Manchester, UK

17        <sup>6</sup> The University of Nottingham, Nottingham, UK

18        <sup>7</sup> Centre for Academic Mental Health, University of Bristol, Bristol, UK

19        <sup>8</sup> Biomedical Research Centre, University of Bristol, Bristol, UK

20        <sup>9</sup> School of Social Policy, University of Birmingham, Birmingham, UK

21        <sup>10</sup> Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK

22        <sup>11</sup> Camden and Islington NHS Foundation Trust, London, UK

23

24        *Corresponding Author:* Professor Rachel Upthegrove, Institute for Mental Health, Wolfson Centre,  
25        University of Birmingham, 52 Pritchatts Road, Birmingham, B15 2TT; Email:

26        [r.upthegrove@bham.ac.uk](mailto:r.upthegrove@bham.ac.uk)

27

28        **FUNDING STATEMENT**

29        EPICare is fully funded by the NIHR Programme Development Grants: PDG Mental Health Call  
30        2021, grant number [NIHR203669]. Birmingham Women's and Children's NHS Foundation Trust  
31        agreed to act as sponsor for this study. The work is supported by the NIHR UCLH Biomedical  
32        Research Centre.

33

34        **COMPETING INTERESTS STATEMENT** NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 GKM has received consultancy fees from ieso. RU reports speaker fees from Sunovion, Springer  
36 Healthcare, Otsuka and Vitaris outside the submitted work and holds unpaid officership with the  
37 British Association for Pharmacology - Honorary General Secretary 2021-2024 and is Deputy  
38 Editor, The British Journal of Psychiatry. The views expressed are those of the author(s) and not  
39 necessarily those of the NIHR.

40

41 Word Count: 4,361; Abstract: 296

42

43 **ABSTRACT**

44 **Introduction:** Early Intervention in Psychosis services are nationally mandated in England to  
45 provide multidisciplinary care to people experiencing first-episode psychosis, which  
46 disproportionately affects deprived and ethnic minority youth. Quality of service provision varies by  
47 region, and people from historically underserved populations have unequal access. In other disease  
48 areas, including stroke and dementia, national digital registries coupled with clinical decision  
49 support systems have revolutionised delivery of equitable, evidence-based interventions to  
50 transform patient outcomes and reduce population-level disparities in care and prognosis. Given  
51 psychosis is ranked the third most burdensome mental health condition by the World Health  
52 Organization, it is essential that we achieve the same parity of health improvements. Here, we  
53 provide details of a co-designed protocol to produce an evidence-based, stakeholder-informed  
54 framework for the build, implementation, and evaluation of a national integrated digital registry and  
55 clinical decision support system for psychosis, known as EPICare (Early Psychosis Informatics for  
56 Care).

57 **Methods and Analysis:** Using a participatory co-design framework, we engaged key stakeholders  
58 (N~40-50) across four meetings to establish the parameters and essential features of EPICare and  
59 identify factors likely to influence adoption and implementation into routine practice. Stakeholders  
60 consisted of organisational, clinical, academic, and patient and public contributors. In collaboration  
61 with National Health Service (NHS) informatics teams, we identified how to retrieve key data items  
62 from Electronic Health Records and subsequently design the software architecture and data model  
63 to create an infrastructure plan for future implementation. Guided by Normalisation Process Theory,  
64 data synthesised from observations of stakeholder meetings and individual interviews (n=10) were  
65 subject to interpretative qualitative analysis. Finally, a co-designed set of guides were produced to  
66 allow for the build, implementation, and evaluation of EPICare in a larger, future study. An  
67 inclusive, representative stakeholder group, fully engaged with the future co-development of  
68 EPICare, was also established.

69

## 70 INTRODUCTION

71 Psychotic disorders, including schizophrenia, are among the most disabling illnesses worldwide and  
72 are often accompanied by enormous personal, family, societal and carer burden (1). Rates of  
73 psychosis are unequally distributed throughout the population, with the highest rates found in  
74 historically underserved communities, younger populations, and those from minority ethnic  
75 backgrounds (2-5). For example, within the UK, people from Black ethnic backgrounds (African,  
76 Caribbean, British) are between 3-5 times more likely to experience a first episode of psychosis than  
77 White British individuals, and there is evidence that rates are also approximately twice as high for  
78 people from Pakistani, Bangladeshi, and mixed ethnic backgrounds in England (2, 6). Further, the  
79 need for treatment delivered by Early Intervention Psychosis (EIP) services in England has been  
80 identified as highest in several historically underserved regions of England, and in related major  
81 conurbations, such as Birmingham, Greater Manchester, Bradford and parts of inner-city London  
82 (6). This need for EIP care is closely aligned to populations exposed to greater structural  
83 disadvantage including multiple deprivation and social fragmentation (6).

84

85 EIP is an internationally adopted model of care, based largely on social inclusion, service user and  
86 care engagement, and relapse prevention. In England, EIP services are nationally commissioned to  
87 provide evidence-based, multidisciplinary care according to eight NICE-based national standards  
88 for people experiencing first-episode psychosis: 1) a maximum waiting time of 14 days from initial  
89 referral to commencement of treatment; 2) offer of cognitive behavioural therapy for psychosis; 3)  
90 take up of family interventions; 4) offer of clozapine after poor response to at least two other  
91 antipsychotic medications; 5) take up of supported employment and education programmes; 6)  
92 annual physical health assessments; 7) offer of interventions relevant to physical health (for  
93 example, smoking cessation, exercise or substance use programmes); and 8) take up or referral to  
94 carer-focused education and support programmes (7). Each care standard is evidence-based, often  
95 from randomised controlled trials. Each standard has demonstrated improvement in patient  
96 outcomes including remission of symptoms, readmission, recovery, premature mortality and  
97 important social and vocational outcomes (8, 9). Importantly, EIP care is cost-effective relative to  
98 other forms of care and management for people with psychosis, and EIP services are highly valued  
99 by service users (10, 11).

100

101 Despite evidence-based standardised targets, only 30-40% of people experiencing psychotic  
102 disorders make a full recovery (12), with evidence of large variation in care (13-16). Longer term  
103 outcomes are equally poor, with increased rates of physical illnesses (17) and life expectancy  
104 reduced by around 15 years compared with people who do not go on to develop severe mental

105 illness (18). This suggests that much work is needed to understand which elements of EIP services  
106 are working, and for whom, and whether they lead to better long term outcomes (16).

107

108 Variation in outcomes may be related to regional or individual disparities in the care offered and  
109 received during EIP, particularly in historically underserved communities where need is greatest,  
110 but where there may be insufficient resources to offer standardised care tailored to the needs of local  
111 populations. For example, recent data indicates that people with psychosis from Black African and  
112 Caribbean backgrounds were 15-30% less likely to receive the equivalent level of cognitive  
113 behavioural therapy for their condition compared to White British people (19). Cross-sectional  
114 survey data from England and Wales has highlighted further inequalities in care, with Black service  
115 users being around 44% less likely to be offered clozapine (19), the only existing medication for  
116 treatment-resistant schizophrenia (13). There is also evidence for disparities in outcomes post-EIP,  
117 with deprivation related to higher rates of relapse and need for continuing care in secondary mental  
118 health services (20). Black and Asian racial minoritized groups are also more likely to continue in  
119 secondary mental health care two years following EIP discharge (21).

120

121 Despite this, data currently being routinely collected via a patient's electronic health record does not  
122 provide accessible, longitudinal, and nationally representative data to determine the magnitude,  
123 causes or consequences of inequitable access to EIP care in England. Relatedly, routine data  
124 collected by EIP services in England does not include measures of symptomatic recovery, usually  
125 the primary outcome for understanding what treatments work for whom, thus preventing us from  
126 developing a national understanding of the clinical effectiveness of treatments in the real world. In  
127 turn, neither does it provide a mechanism for immediately improving clinical practice by feeding  
128 back real-time actionable insights that would allow treatments to be targeted and tailored to  
129 individual patient needs. For example, whilst all EIP providers send data on broad levels of service  
130 use into NHS Digital's Mental Health Services Dataset, the dataset is less suited to ascertain  
131 accurate estimates of the incidence of psychotic disorders in England, because current methods of  
132 data collection do not differentiate between people engaging in EIP treatment for their first ever  
133 episode of psychosis from those who may have existing psychosis, but engage in treatment in a new  
134 EIP service for the first time. Further, Mental Health Services Dataset data does not record whether  
135 those engaging with EIP treatment later fulfil diagnostic criteria for psychotic disorder. The Mental  
136 Health Services Dataset also does not allow us to understand what treatments are delivered to  
137 whom, and when, nor their impact on patient recovery and other downstream outcomes.  
138 Furthermore, the pioneering National Clinical Audit of Psychosis (22), which has assessed service  
139 fidelity annually since 2017, is a retrospective, cross-sectional manual audit of up to 100 patients

140 with first-episode psychosis in each EIP team in England (22). Although plans exist to revise the  
141 data collection methodology, current practice reduces data quality, delays service improvement, and  
142 diverts finite EIP resources away from frontline care. There are also no plans for the audit to  
143 provide real-time feedback of data to clinical teams. These issues could be eliminated by the  
144 provision of a prospectively-collected national digital psychosis registry, able to supply actionable  
145 insights in real time to patients, clinical teams, service managers and policymakers via an embedded  
146 clinical decision support system (CDSS).

147

148 We propose to revolutionise the use of electronic health record data to improve national, local, and  
149 individual clinical decision-making and promote better patient and public health outcomes for  
150 people experiencing first-episode psychosis, by carefully developing and demonstrating the utility  
151 of a prospectively collected digital registry and CDSS in England, capable of being implemented  
152 nationally. This would provide standardised information to understand the treated burden of  
153 psychosis in the NHS; ensure equitable, responsive, local resource allocation; support reliable,  
154 quick, and efficient identification and targeting of any local, regional or group-based disparities in  
155 access to care; and improve patient pathways through care and downstream outcomes, including  
156 recovery; and finally, enhance understanding of the relationship between interventions provided and  
157 outcomes, as well as the relationship between clinical and social characteristics and outcomes.

158

159 The potential for further record linkage to other health and social domains also offers the prospect  
160 of integrating prospectively collected data from other routine sources including primary care, Office  
161 for National Statistics mortality, the Office for National Statistics Census, the National Pupil  
162 Database, and Hospital Episode Statistics. This would provide a deeply phenotyped, longitudinal  
163 database for clinical and policy decision making. It would also support gold standard research in  
164 clinical psychiatry, experimental medicine, and observational epidemiology, to identify, understand,  
165 and address the causes and consequences of disparities in health and patient treatment, as well as  
166 improve downstream outcomes for people experiencing psychosis.

167

168 Digital registries have been deployed successfully in the UK for other disease areas such as stroke,  
169 cancer, cystic fibrosis, and dementia (23-28). For example, in the UK, a national stroke registry has  
170 transformed patient care and outcomes, with early recognition of different patterns of stroke  
171 presentation, focused treatment on previously untreated risk factors, and targeted interventions for  
172 improving cognitive impairment (27). In cancer care, tailored interventions based on risk profile  
173 have extended lives for thousands of people (28). Yet there are no contemporary examples of digital  
174 registries for any secondary care-treated mental health condition listed in the Health Research

175 Classification System mental health category, nor within the international literature, and no specific  
176 CDSS for any mental health condition. Integration of a patient-centered digital registry and CDSS  
177 for psychosis could be equally transformative and give parity of esteem to one of the most common  
178 and disabling set of mental health disorders – psychosis – where there is already a well-developed  
179 national infrastructure of EIP services.

180

181 To achieve this paradigmatic change in mental health care, our aim is to develop, evaluate and  
182 establish a national psychosis registry and CDSS, known as EPICare (Early Psychosis Informatics  
183 for Care) in three stages:

184

- 185 • Stage 1: Establish a multidisciplinary and multisector stakeholder network to co-design, de-  
186 risk, and define the framework and protocols required to build and implement EPICare as a  
187 successful national registry and CDSS.
- 188
- 189 • Stage 2: Build, pilot, implement, and evaluate the ability of the EPICare platform to improve  
190 patient care, enhance service delivery, reduce disparities in care, and demonstrate cost-  
191 effectiveness in five demonstrator NHS Trusts, serving underserved and diverse populations  
192 with substantial need for EIP care in England.
- 193
- 194 • Stage 3: Subject to successful implementation and evaluation, seek NHS adoption of  
195 EPICare for rollout to all EIP services in England.

196

## 197 **AIMS AND OBJECTIVES**

198 In this paper, we report the protocol for the programme development phase of our activity (Stage 1),  
199 in which we aimed to co-design and produce a framework and protocols for onward building,  
200 implementation, piloting, and evaluation of a national integrated, patient-centered digital registry  
201 and CDSS for psychosis.

202

203 To meet this aim, we specifically addressed the following objectives:

204

- 205 1. Establish a network with strong patient and public involvement and engagement (PPIE) and  
206 other essential stakeholders to identify essential and desirable elements and minimize  
207 unforeseen challenges (Work Package 1).

208

- 209 2. Address key questions on informatics architecture, infrastructure, governance, and  
210 integration plans to facilitate onward development and testing of EPICare in diverse NHS  
211 Trusts (Work Package 2).  
212
- 213 3. Identify implementation factors from the outset to ensure they are considered in designing,  
214 implementing, and sustaining the future deployment of EPICare in a measurable way (Work  
215 Package 3).  
216

## 217 **METHODS AND ANALYSIS**

218

### 219 **Study Design**

220 We conducted three concurrent work packages over 12 months, with reciprocal knowledge  
221 exchange between work packages, coordinated via fortnightly Programme Management Group  
222 meetings. Figure 1 provides a schematic of work packages. The Programme Management Group  
223 contained lived experience facilitator, lived experience member, clinicians working in early  
224 psychosis and academic members from epidemiology, NHS health informatics, data and  
225 implementation science. The EPICare study was reviewed and granted full approval by the Health  
226 Research Authority on November 8, 2021 (Ref: 306234).  
227

#### 228 *Work Package 1: Stakeholder co-design of the EPICare registry and CDSS*

229 A participatory co-design framework previously established for informatics in mental health (29)  
230 was used to engage a diverse network of stakeholders in the co-design process, including clinicians,  
231 academics, policymakers, and PPIE members. Due to the COVID-19 pandemic, workshops were  
232 convened online. Whilst this enhanced the scope for collaboration between centres in the study,  
233 there were also potential drawbacks of this approach, which included PPIE needing to have access  
234 to, and know-how of technology. Second, hosting face-to-face meetings on neutral ground in an  
235 approachable format may have helped to removed traditional power structures. The workshops were  
236 in a facilitator-led, semi-structured format, including presentations, whole-group discussions, and  
237 themed breakout activities (card-sort tasks, small group discussion) with both mixed (random  
238 allocation) and streamed group (by broad stakeholder type) sessions on a per-task basis. Essential  
239 materials were circulated to stakeholders in advance of each meeting. We also convened additional  
240 online preparatory sessions for PPIE stakeholders, led by our PPIE coordinator, to aid understanding  
241 and participation in the main workshops. Registry and CDSS goals were examined by stakeholders,  
242 who reviewed, refined, and identified a core set of essential and desirable measures that should be



243 collected in the integrated EPICare registry and CDSS, across four domains: sociodemographic  
244 measures, treatment measures, patient-reported outcome measures, and clinician-reported outcome  
245 measures (CROMS).

246

247 To facilitate this process, stakeholders were provided with a list of data already recorded in  
248 electronic health records in EIP services, in addition to information on data relevant to the eight  
249 nationally mandated NICE standards for EIP care (30) (Health of the Nation Outcomes Scales  
250 [HoNOS] on functioning; quality of life and treatment satisfaction [DIALOG], and patient-reported  
251 recovery [QPR]). This was supplemented with a minimal set of other initial measures recognized as  
252 potentially relevant by the Programme Management Group based on expert knowledge, prior to the  
253 first workshop. Examples included symptom ratings, duration of untreated psychosis, and  
254 genotyping, amongst others. In Workshops 1 and 2, stakeholders were asked to review, refine,  
255 prioritize, and suggest additions or subtractions from this list, with other data that may not currently  
256 be routinely collected, but considered by stakeholders to be essential or desirable. The group also  
257 explored what barriers to implementation and uptake may be encountered in EPICare (e.g., data  
258 security and ownership, time for completion, digitising of routine data currently collected on paper).  
259 Similarly, in Workshop 3, stakeholders identified the essential and desirable features of a CDSS to  
260 provide timely actionable insights for patients and clinicians, including potential clinician prompts  
261 to complete health assessments aligned to NICE standards for EIP care.

262

263 After these three initial workshops, we synthesised all information gathered via a modified Delphi  
264 approach involving all stakeholders and members of the research team, to develop a consensus of  
265 data priorities (what, when, by whom). We shared this with the members of Work Package 2 to  
266 understand technical and governance barriers to implementation to further refine our framework to  
267 identify a set of “must have” and “could have” data elements. Finally, in Workshop 4, we presented  
268 our proposed framework to stakeholders, sought further feedback, and outlined our plans for Stage 2  
269 of EPICare development. From our initial stakeholder network, we sought to retain a representative  
270 group of stakeholders for our Stage 2 activity, who will continue to guide the pilot, testing, and  
271 evaluation throughout the project, providing a reference point for rapid prototyping and end-user  
272 consultation, acceptance, and build.

273

274 *Work Package 2: Informatics architecture, infrastructure and integration: framework, protocol &*  
275 *toolkit*

276 Work Package 2 aimed to reduce technical and governance challenges in the future full build of  
277 EPICare by addressing key questions and unknowns. Based on prior experience and knowledge, the

278 area of biggest technical risk for EPICare is the retrieval of data from electronic health records and  
279 standardisation of this into a common data model, whilst ensuring compliance with information  
280 governance and ethical standards. Previous work by the group involved auditing all EIP services  
281 that are part of the National Institute for Health Research (NIHR)-Mental Health Translational  
282 Research Collaboration in Early Psychosis (MHTRC-Early Psychosis), to inform understanding of  
283 the existing infrastructure, capacity, capabilities, and limitations around designing and developing  
284 the EPICare platform for potential national implementation. This initial scoping work has  
285 highlighted several different electronic health records in use as well as different ways of capturing  
286 and storing relevant data in each of the Trusts.

287

288 To build on this knowledge, Health Informatics specialists within the research team contacted and  
289 liaised with five NHS Trusts, including Greater Manchester Mental Health NHS Foundation Trust,  
290 Birmingham Women's and Children's NHS Foundation Trust, Cambridgeshire and Peterborough  
291 NHS Foundation Trust, Nottinghamshire Healthcare NHS Foundation Trust and Camden and  
292 Islington NHS Foundation Trust. Information Technology team leads and proposed demonstrator  
293 sites were identified, gathering information to further understand what electronic health record  
294 system is used by each trust; what relevant data are currently captured in the electronic health  
295 record (key foci: eight NICE standards for first-episode psychosis treatment); how that data can be  
296 retrieved, such as via Application Programming Interface or through regular exports; how the data  
297 can, and should be secured during retrieval, complying to the highest information governance  
298 standards; and the data formats used for each type of data.

299

300 Once this information was captured from all Trusts, it was then used alongside the information  
301 gathered from the stakeholders in Work Package 1 to develop and document key requirements for  
302 the EPICare system; software architecture for the registry and CDSS; data model design including  
303 standardisation of data items into a common format; security threat model including planned  
304 treatments for identified threats; proposed infrastructure to include an appropriate hosting solution,  
305 such as a secure cloud environment; and an integration plan for retrieval of data from each Trust  
306 electronic health record.

307

308 This was drafted into an overall framework document and set of technical infrastructure and  
309 information governance protocols and toolkits to inform the future build, pilot, implementation, and  
310 evaluation of the EPICare platform. With all of this in place, the technical and governance  
311 challenges for the main programme grant for applied research application should be significantly  
312 reduced.

313

314 *Work Package 3: Implementation evaluation framework*

315 Working in parallel and in collaboration with the members of Work Packages 1 and 2, the purpose  
316 of this work package was to establish the preliminary implementation framework for the subsequent  
317 testing and roll-out of EPICare. Founded on the idea that implementation research should be  
318 integrated throughout all stages of innovation development rather than at ‘end-stage’, this involved  
319 understanding the distinct and interconnected implementation issues within the stages of problem  
320 definition; iterative evidence-building, intervention conceptualisation, development and testing; and  
321 subsequent roll-out, experimentation, and embedding in different service settings. With particular  
322 reference to EPICare, this involved understanding how the earlier stages of stakeholder engagement  
323 contributed to intervention development and, at the same time, how stakeholders perceived  
324 challenges to future adoption and use. With regards to PPIE stakeholders (Work Package 1), this  
325 involved understanding views about: a) current challenges in EIP care; b) how clinical registries and  
326 CDSS might influence care and service improvement; c) expectations about how interventions  
327 might be utilised in standard practice, and d) participants’ experiences of the co-design process. We  
328 also studied the early-stage activities of the health informatics team (Work Package 2) to understand  
329 the explicit and tacit design assumptions; the contingencies presented by current technological  
330 parameters; the influence of prevailing governance arrangements; and importantly, to understand  
331 and evidence the interaction between the relative influence of multiple stakeholders in the co-design  
332 process. This evidence will be brought together with existing implementation science frameworks,  
333 such as Normalisation Process Theory (31), in conjunction with complementary insights drawn  
334 from Science and Technology Studies (32, 33).

335 Normalisation Process Theory helps understand how service innovations are implemented,  
336 embedded, and normalised within organisations, to the point where new practices are no longer  
337 regarded as new. It is different from other implementation models because it focuses on the specific  
338 ‘work’ undertaken by social actors to implement innovations into everyday practice whilst taking  
339 into consideration the interplay between actions, contexts, and objects. Normalisation Process  
340 Theory has four linked constructs: ‘coherence’, or the work of making sense of an innovation;  
341 ‘cognitive participation’, or the work involved when engaging with an innovation; ‘collective  
342 action’, or the combined work of integrating new practices into existing skills, relationships, and  
343 contexts; and ‘reflexive monitoring’, or the work of continually appraising and adapting to the  
344 introduction of new practices. It has been widely used to explain the factors that shape the  
345 implementation of complex interventions (31).

346

347 Field researchers directly observed all four stakeholder co-design workshops and considered the  
348 influence of multiple social, cultural and organisational factors on the co-design process. They also  
349 observed a selection of key design meetings held between the technologists, NHS Trust partners,  
350 and other stakeholder groups to map and describe the iterative development of EPICare. Each  
351 researcher recorded their observations following an agreed semi-structured guide which were then  
352 aggregated for analysis.

353

354 To clarify the observational data, qualitative semi-structured interviews guided by the constructs  
355 from Normalisation Process Theory were then conducted with all stakeholder groups to understand  
356 the factors likely to influence subsequent implementation of EPICare. An initial set of questions and  
357 topics derived from the study objectives were used to systematically code interview transcripts and  
358 develop themes. This was piloted on four transcripts by two researchers, before agreeing to a  
359 revised set of codes, followed by further coding of remaining transcripts. Interviews focused on the  
360 different cognitive-cultural perspectives of each stakeholder group, their experiences of  
361 participating in the co-design process, and their perceptions about their influence on the co-design,  
362 together with their recommendations for subsequent development and testing.

363

#### 364 *Study Participants*

365 Participants were recruited between November and December 2021. We recruited forty participants  
366 across all stakeholder workshops (Work Package 1). This included at least ten people with lived  
367 experience of psychosis, and ideally, lived experience of early intervention, to form the PPIE  
368 stakeholder group. PPIE members were recruited from the Birmingham University Youth Advisory  
369 Group, Cambridgeshire & Peterborough Foundation Trust, Bristol Lived Experience Advisory  
370 Panel and PPIE networks at University College London, including those associated with the  
371 National Institute for Health Research Mental Health Policy Research Unit. As an  
372 acknowledgement of the time and effort involved in taking part in the study, PPIE participants were  
373 reimbursed in line with the INVOLVE payment policy ([www.involve.org.uk](http://www.involve.org.uk)), which equates to £25  
374 per hour of participation.

375

376 The remaining thirty participants were recruited from the breadth of multidisciplinary care in EIP  
377 services (psychiatrists, psychologists, occupational therapists, social workers, and nurses), in  
378 addition to stakeholders from the charitable sector, NHS England, policymakers, and other  
379 academics, for facilitated group meetings. The clinical collaborators were recruited from NHS  
380 Trusts serving diverse and underserved areas with a combined population of approximately 3.73m  
381 people (10.1% of the English population at risk for psychosis): Birmingham Women's and

382 Children's Trust, Manchester Health and Care NHS Foundation Trust, Camden and Islington NHS  
383 Foundation Trust, Avon and Wiltshire Mental Health Partnership Trust, and Cambridgeshire &  
384 Peterborough Foundation Trust. Attendance at the stakeholder group meetings was taken as consent  
385 for this process and no individual written consent was required from stakeholders (including PPIE).

386

387 All stakeholders were also invited to participate in individual qualitative interviews in Work  
388 Package 3 to ensure that we selected a representative subset of each stakeholder group from our  
389 Work Package 1 stakeholder meetings. Written informed consent was obtained and interviewees  
390 were given a unique participant identification number, which was used throughout the transcription  
391 of interviews to ensure anonymity.

392

393 Given the online group format of the stakeholder workshops, individual participants attending these  
394 workshops were identifiable to each other and to the authors. However, the identities of participants  
395 who consented to an individual qualitative interview were known only to the interviewer, and as  
396 noted above, interviewees were assigned a unique participant identification number to ensure their  
397 anonymity during the transcription of their interviews.

398

### 399 *Analysis*

400 All interviews were recorded and transcribed. For quality control, transcript summaries were shared  
401 with participants and feedback elicited as to their veracity. Observation notes of the stakeholder  
402 workshops and transcripts of the individual interviews were subject to interpretative qualitative  
403 analysis, guided by the Normalisation Process Theory implementation science framework.

404 Preliminary data analysis of observation notes involved producing short descriptive summaries of  
405 field observations, for the purpose of summarising and sharing data with the study team. NVivo  
406 software was used to organise and analyse the qualitative observational and transcribed interview  
407 data. An iterative coding process was followed with data being subject to systematic close reading  
408 and coding. Through sharing and deliberating preliminary codes and interpretations with the wider  
409 study team and through the processes of constant comparison, secondary inductive and  
410 interpretative themes were developed. At this stage, the constructs of Normalisation Process Theory  
411 were used to further analyse and explain the study findings. Through discussion and disputation  
412 with PPIE, clinicians, and the project team, inferences were made about how the implementation  
413 science framework should be further refined.

414

## 415 **DISCUSSION**

416

417 The purpose of this study is to develop, implement and evaluate a national integrated, patient-  
418 centered digital registry and CDSS for psychosis (EPICare) to improve national, local and  
419 individual clinical decision-making and promote improved outcomes for people experiencing first-  
420 episode psychosis. The EPICare registry and CDSS potentially represent a paradigmatic shift, as  
421 they would be the first patient-centered digital registry and CDSS for psychosis, one of the most  
422 common and disabling mental health disorders disproportionately affecting deprived and  
423 disadvantaged youth. By combining routine, systematic, prospective data collection via a national  
424 digital registry with real-time actionable insights delivered to patients, clinical teams, service  
425 managers and policymakers via an embedded CDSS, EPICare aims to improve patient care, enhance  
426 service delivery, reduce disparities in care, and further our understanding of the relationship  
427 between the interventions offered to, and received by, young people receiving EIP care and  
428 outcomes. A further aim of the study is to demonstrate cost-effectiveness in five demonstrator NHS  
429 Trusts serving underserved and diverse populations with substantial need for EIP care in England.

430  
431 In this paper, we have reported the protocol for the programme development phase of this study  
432 (Stage 1), in which we aimed to co-design and produce a framework and protocols for onward  
433 building, implementation, piloting, and evaluation of the EPICare registry and CDSS. Strengths of  
434 this first phase of the study include the use of a participatory design to co-design a framework for  
435 EPICare with input from diverse relevant stakeholders, including lived experience experts and  
436 clinical, academic, technologist and organisational stakeholders. By engaging multiple stakeholders  
437 in an iterative co-design process and using qualitative methods to capture and synthesise rich data  
438 representing a variety of perspectives, we have succeeded in establishing a network with strong  
439 patient and public involvement and engagement (PPIE) and representation from other essential  
440 stakeholder groups and in collaboratively identifying essential and desirable elements of the  
441 EPICare platform (Work Package 1). We have also worked to proactively identify and minimize  
442 potential challenges and barriers to uptake and implementation (Work Package 3), including by  
443 addressing key questions related to informatics architecture, infrastructure, governance, and  
444 integration in diverse NHS Trusts (Work Package 2).

445  
446 While we have achieved all of the objectives set out for the first phase of this study, it is worth  
447 noting that adoption and integration of all the desirable platform elements identified by stakeholders  
448 may not be feasible or pragmatic for the initial build of the data model. This will be tested in our  
449 next stage.

450

451 Next steps for the EPICare study include Stage 2 building, piloting, implementation, and evaluation  
452 of the EPICare platform in five demonstrator NHS Trusts serving underserved and diverse  
453 populations with substantial need for EIP care in England. If successful, this will be followed by  
454 Stage 3, in which we will seek NHS adoption of EPICare for rollout to all EIP services in England.

455

## 456 **ETHICS AND DISSEMINATION**

457 The EPICare programme has been granted full approval by the Health Research Authority (Ref:  
458 306234).

459 The results will be disseminated through peer-reviewed journals, conference presentations, media  
460 outlets, the internet, and various community / stakeholder engagement activities.

461

## 462 **AUTHORS' CONTRIBUTIONS**

463 R.U. and J.B.K. are joint project leads and hold joint senior authorship. S.L.G. drafted the  
464 manuscript with further input from R.U. and J.B.K., S.J., G.K.M., M.A.P., N.C., J.W., J.A., R.D.,  
465 M.M., S.A., T.J.W., J.K., Y.L., T.B. and S.S. also contributed to the study as well as provided  
466 comments on the manuscript. All authors approved the final version.

467

468

469

470

471

## 472 **REFERENCES**

- 473 1. Heiden W, Häfner H. The epidemiology of onset and course of schizophrenia 2000. 292-303 p.
- 474 2. Kirkbride JB, Errazuriz A, Croudace TJ, Morgan C, Jackson D, Boydell J, et al. Incidence of  
475 schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. *PLoS*  
476 *One*. 2012;7(3):e31660.
- 477 3. Jongsma HE, Turner C, Kirkbride JB, Jones PB. International incidence of psychotic disorders,  
478 2002-17: a systematic review and meta-analysis. *Lancet Public Health*. 2019;4(5):e229-e44.
- 479 4. March D, Hatch SL, Morgan C, Kirkbride JB, Bresnahan M, Fearon P, et al. Psychosis and place.  
480 *Epidemiol Rev*. 2008;30:84-100.
- 481 5. O'Donoghue B, Roche E, Lane A. Neighbourhood level social deprivation and the risk of psychotic  
482 disorders: a systematic review. *Soc Psychiatry Psychiatr Epidemiol*. 2016;51(7):941-50.
- 483 6. McDonald K, Ding T, Ker H, Dliwayo TR, Osborn DPJ, Wohland P, et al. Using epidemiological  
484 evidence to forecast population need for early treatment programmes in mental health: a generalisable  
485 Bayesian prediction methodology applied to and validated for first-episode psychosis in England. *Br J*  
486 *Psychiatry*. 2021;219(1):383-91.
- 487 7. NICE. QS80: Psychosis and schizophrenia in adults. National Institute for Health and Care  
488 Excellence; 2015.
- 489 8. Bird V, Premkumar P, Kendall T, Whittington C, Mitchell J, Kuipers E. Early intervention services,  
490 cognitive-behavioural therapy and family intervention in early psychosis: systematic review. *Br J Psychiatry*.  
491 2010;197(5):350-6.

- 492 9. Anderson KK, Norman R, MacDougall A, Edwards J, Palaniyappan L, Lau C, et al. Effectiveness of  
493 Early Psychosis Intervention: Comparison of Service Users and Nonusers in Population-Based Health  
494 Administrative Data. *Am J Psychiatry*. 2018;175(5):443-52.
- 495 10. McCrone P, Craig TKJ, Power P, Garety PA. Cost-effectiveness of an early intervention service for  
496 people with psychosis. *British Journal of Psychiatry*. 2010;196(5):377-82.
- 497 11. Lester H, Marshall M, Jones P, Fowler D, Amos T, Khan N, et al. Views of young people in early  
498 intervention services for first-episode psychosis in England. *Psychiatr Serv*. 2011;62(8):882-7.
- 499 12. Lally J, Ajnakina O, Stubbs B, Cullinane M, Murphy KC, Gaughran F, et al. Remission and recovery  
500 from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies.  
501 *British Journal of Psychiatry*. 2017;211(6):350-8.
- 502 13. Stokes I, Griffiths SL, Jones R, Everard L, Jones PB, Fowler D, et al. Prevalence of treatment  
503 resistance and clozapine use in early intervention services. *BJPsych Open*. 2020;6(5):e107.
- 504 14. Fisher HL, Johnson S, Major B, Rahaman N, Rammou A, Fisher HL, et al.
- 505 15. Marwaha S, Thompson A, Upthegrove R, Broome MR. Fifteen years on - early intervention for a  
506 new generation. *Br J Psychiatry*. 2016;209(3):186-8.
- 507 16. Griffiths SL, Lalouis PA, Wood SJ, Upthegrove R. Heterogeneity in treatment outcomes and  
508 incomplete recovery in first episode psychosis: does one size fit all? *Transl Psychiatry*. 2022;12(1):485.
- 509 17. Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The Lancet Psychiatry  
510 Commission: a blueprint for protecting physical health in people with mental illness. *The Lancet Psychiatry*.  
511 2019;6(8):675-712.
- 512 18. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in  
513 schizophrenia: a systematic review and meta-analysis. *The Lancet Psychiatry*. 2017;4(4):295-301.
- 514 19. Morris RM, Sellwood W, Edge D, Colling C, Stewart R, Cupitt C, et al. Ethnicity and impact on the  
515 receipt of cognitive-behavioural therapy in people with psychosis or bipolar disorder: an English cohort  
516 study. *BMJ Open*. 2020;10(12):e034913.
- 517 20. Puntis S, Oke J, Lennox B. Discharge pathways and relapse following treatment from early  
518 intervention in psychosis services. *BJPsych Open*. 2018;4(5):368-74.
- 519 21. Griffiths SL, Bogatsu T, Longhi M, Butler E, Alexander B, Bandawar M, et al. Five-year illness  
520 trajectories across racial groups in the UK following a first episode psychosis. *Social Psychiatry and*  
521 *Psychiatric Epidemiology*. 2023;58(4):569-79.
- 522 22. NCAP. National Clinical Audit in Psychosis Audit 2021.
- 523 23. Heuschmann PU, Grieve AP, Toschke AM, Rudd AG, Wolfe CDA. Ethnic Group Disparities in 10-  
524 Year Trends in Stroke Incidence and Vascular Risk Factors. *Stroke*. 2008;39(8):2204-10.
- 525 24. Kelsey EA, Njeru JW, Chaudhry R, Fischer KM, Schroeder DR, Croghan IT. Understanding User  
526 Acceptance of Clinical Decision Support Systems to Promote Increased Cancer Screening Rates in a Primary  
527 Care Practice. *Journal of Primary Care & Community Health*. 2020;11:2150132720958832.
- 528 25. Taylor-Robinson D, Archangelidi O, Carr SB, Cosgriff R, Gunn E, Keogh RH, et al. Data Resource  
529 Profile: The UK Cystic Fibrosis Registry. *International Journal of Epidemiology*. 2017;47(1):9-10e.
- 530 26. Stephan BCM, Siervo M, Brayne C. How can population-based studies best be utilized to reduce the  
531 global impact of dementia? Recommendations for researchers, funders, and policymakers. *Alzheimers*  
532 *Dement*. 2020;16(10):1448-56.
- 533 27. Langhorne P, Taylor G, Murray G, Dennis M, Anderson C, Bautz-Holter E, et al. Early supported  
534 discharge services for stroke patients: a meta-analysis of individual patients' data. *The Lancet*.  
535 2005;365(9458):501-6.
- 536 28. Mazo C, Kearns C, Mooney C, Gallagher WM. Clinical Decision Support Systems in Breast Cancer:  
537 A Systematic Review. *Cancers (Basel)*. 2020;12(2).
- 538 29. Ospina-Pinillos L, Davenport T, Mendoza Diaz A, Navarro-Mancilla A, Scott EM, Hickie IB. Using  
539 Participatory Design Methodologies to Co-Design and Culturally Adapt the Spanish Version of the Mental  
540 Health eClinic: Qualitative Study. *J Med Internet Res*. 2019;21(8):e14127.
- 541 30. (NICE) NifHaCE. Psychosis and Schizophrenia in Adults: Treatment and Management. London:  
542 Royal College of Psychiatrists; 2014.
- 543 31. Murray E, Treweek S, Pope C, MacFarlane A, Ballini L, Dowrick C, et al. Normalisation process  
544 theory: a framework for developing, evaluating and implementing complex interventions. *BMC Medicine*.  
545 2010;8(1):63.



- 546 32. Robertson A, Cresswell K, Takian A, Petrakaki D, Crowe S, Cornford T, et al. Implementation and  
547 adoption of nationwide electronic health records in secondary care in England: qualitative analysis of interim  
548 results from a prospective national evaluation. *Bmj*. 2010;341:c4564.
- 549 33. Ainsworth J, Harper R. The PsyGrid Experience: Using Web Services in the Study of Schizophrenia.  
550 2008. p. 365-86.

551

medRxiv preprint doi: <https://doi.org/10.1101/2023.06.02.23290899>; this version posted June 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 1. Study design.